Advertisement
Mayo Clinic Proceedings Home

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

      OBJECTIVE

      To establish accurate, up-to-date, baseline epidemiological data for herpes zoster (HZ) before the introduction of the recently licensed HZ vaccine.

      METHODS

      Using data from January 1, 1996, to October 15, 2005, we conducted a population-based study of adult residents (≥22 years) of Olmsted County, MN, to determine (by medical record review) the incidence of HZ and the rate of HZ-related complications. Incidence rates were determined by age and sex and adjusted to the US population.

      RESULTS

      A total of 1669 adult residents with a confirmed diagnosis of HZ were identified between January 1, 1996, and December 31, 2001. Most (92%) of these patients were immunocompetent and 60% were women. When adjusted to the US adult population, the incidence of HZ was 3.6 per 1000 person-years (95% confidence interval, 3.4-3.7), with a temporal increase from 3.2 to 4.1 per 1000 person-years from 1996 to 2001. The incidence of HZ and the rate of HZ-associated complications increased with age, with 68% of cases occurring in those aged 50 years and older. Postherpetic neuralgia occurred in 18% of adult patients with HZ and in 33% of those aged 79 years and older. Overall, 10% of all patients with HZ experienced 1 or more nonpain complications.

      CONCLUSIONS

      Our population-based data suggest that HZ primarily affects immunocompetent adults older than 50 years; 1 in 4 experiences some type of HZ-related complication.
      CI (confidence interval), HIV (human immunodeficiency virus), HZ (herpes zoster), PHN (postherpetic neuralgia), REP (Rochester Epidemiology Project), VZV (varicella zoster virus)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Kimberlin DW
        • Whitley RJ
        Varicella-zoster vaccine for the prevention of herpes zoster.
        N Engl J Med. 2007; 356: 1338-1343
        • Oxman MN
        Vaccination to prevent herpes zoster and postherpetic neuralgia.
        Hum Vaccin. 2007 Mar-Apr; 3 (Epub 2007 Mar 23.): 64-68
        • Oxman MN
        • Levin MJ
        • Johnson GR
        • Shingles Prevention Study Group
        • et al.
        A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
        N Engl J Med. 2005; 352: 2271-2284
        • Lydick E
        • Epstein RS
        • Himmelberger D
        • White CJ
        Herpes zoster and quality of life: a self-limited disease with severe impact.
        Neurology. 1995; 45: S52-S53
        • Katz J
        • Cooper EM
        • Walther RR
        • Sweeney EW
        • Dworkin RH
        Acute pain in herpes zoster and its impact on health-related quality of life.
        Clin Infect Dis. 2004 Aug 1; 39 (Epub 2004 Jul 19.): 342-348
        • Gnann Jr, JW
        • Whitley RJ
        Clinical practice: herpes zoster.
        N Engl J Med. 2002; 347: 340-346
        • Wood MJ
        • Kay R
        • Dworkin RH
        • Soong SJ
        • Whitley RJ
        Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials.
        Clin Infect Dis. 1996; 22: 341-347
        • Dworkin RH
        • Johnson RW
        • Breuer J
        • et al.
        Recommendations for the management of herpes zoster.
        Clin Infect Dis. 2007; 44: S1-S26
        • Argoff CE
        • Katz N
        • Backonja M
        Treatment of postherpetic neuralgia: a review of therapeutic options.
        J Pain Symptom Manage. 2004; 28: 396-411
        • Watson CP
        • Watt VR
        • Chipman M
        • Birkett N
        • Evans RJ
        The prognosis with postherpetic neuralgia.
        Pain. 1991; 46: 195-199
        • Douglas MW
        • Johnson RW
        • Cunningham AL
        Tolerability of treatments for postherpetic neuralgia.
        Drug Saf. 2004; 27: 1217-1233
        • Rowbotham M
        • Harden N
        • Stacey B
        • Bernstein P
        • Magnus-Miller L
        Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.
        JAMA. 1998; 280: 1837-1842
        • Sabatowski R
        • Galvez R
        • Cherry DA
        • 1008-045 Study Group
        • et al.
        Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.
        Pain. 2004; 109: 26-35
        • Parsons B
        • Tive L
        • Huang S
        Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.
        Am J Geriatr Pharmacother. 2004; 2: 157-162
        • Schmader K
        Herpes zoster in older adults.
        Clin Infect Dis. 2001 May 15; 32 (Epub 2001 Apr 17.): 1481-1486
        • Insinga RP
        • Itzler RF
        • Pellissier JM
        • Saddier P
        • Nikas AA
        The incidence of herpes zoster in a United States administrative database.
        J Gen Intern Med. 2005; 20: 748-753
        • Donahue JG
        • Choo PW
        • Manson JE
        • Platt R
        The incidence of herpes zoster.
        Arch Intern Med. 1995; 155: 1605-1609
        • Rothberg MB
        • Virapongse A
        • Smith KJ
        Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
        Clin Infect Dis. 2007 May 15; 44 (Epub 2007 Apr 3.): 1280-1288
        • Hornberger J
        • Robertus K
        Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
        Ann Intern Med. 2006; 145: 317-325
        • Scott FT
        • Johnson RW
        • Leedham-Green M
        • Davies E
        • Edmunds WJ
        • Breuer J
        The burden of Herpes Zoster: a prospective population based study.
        Vaccine. 2006 Feb 27; 24 (Epub 2005 Sep 30.): 1308-1314
        • Mullooly JP
        • Riedlinger K
        • Chun C
        • Weinmann S
        • Houston H
        Incidence of herpes zoster, 1997-2002.
        Epidemiol Infect. 2005; 133: 245-253
        • Hope-Simpson RE
        The nature of herpes zoster: a long-term study and a new hypothesis.
        Proc R Soc Med. 1965; 58: 9-20
        • Ragozzino MW
        • Melton III, LJ
        • Kurland LT
        • Chu CP
        • Perry HO
        Population-based study of herpes zoster and its sequelae.
        Medicine (Baltimore). 1982; 61: 310-316
        • Opstelten W
        • Mauritz JW
        • de Wit NJ
        • van Wijck AJ
        • Stalman WA
        • van Essen GA
        Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database.
        Fam Pract. 2002; 19: 471-475
        • Czernichow S
        • Dupuy A
        • Flahault A
        • Chosidow O
        Herpes zoster: incidence study among “sentinel” general practitioners. [in French].
        Ann Dermatol Venereol. 2001; 128: 497-501
        • Melton III, LJ
        History of the Rochester Epidemiology Project.
        Mayo Clin Proc. 1996; 71: 266-274
        • Kurland LT
        • Molgaard CA
        The patient record in epidemiology.
        Sci Am. 1981; 245: 54-63
        • Yawn BP
        • Yawn RA
        • Geier GR
        • Xia Z
        • Jacobsen SJ
        The impact of requiring patient authorization for use of data in medical records research.
        J Fam Pract. 1998; 47: 361-365
        • Jacobsen SJ
        • Xia Z
        • Campion ME
        • et al.
        Potential effect of authorization bias on medical record research.
        Mayo Clin Proc. 1999; 74: 330-338
        • Dworkin RH
        • Corbin AE
        • Young Jr, JP
        • et al.
        Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.
        Neurology. 2003; 60: 1274-1283
        • Rice ASC
        • Maton S
        • Postherpetic Neuralgia Study Group
        Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study.
        Pain. 2001; 94: 215-224
        • Cunningham AL
        • Dworkin RH
        The management of post-herpetic neuralgia [editorial].
        BMJ. 2000; 321: 778-779
        • Dworkin RH
        • Carrington D
        • Cunningham A
        • et al.
        Assessment of pain in herpes zoster: lessons learned from antiviral trials.
        Antiviral Res. 1997; 33: 73-85
        • Yawn BP
        • Wollan P
        Interrater reliability: completing the methods description in medical records review studies.
        Am J Epidemiol. 2005; 161: 974-977
        • Brisson M
        • Edmunds WJ
        Epidemiology of varicella-zoster virus in England and Wales.
        J Med Virol. 2003; 70: S9-S14
        • di Luzio Paparatti UD
        • Arpinelli F
        • Visona G
        Herpes zoster and its complications in Italy: an observational survey.
        J Infect. 1999; 38: 116-120
        • Brisson M
        • Edmunds WJ
        • Law B
        • et al.
        Epidemiology of varicella zoster virus infection in Canada and the United Kingdom.
        Epidemiol Infect. 2001; 127: 305-314
        • Russell ML
        • Schopflocher DP
        • Svenson L
        • Virani SN
        Secular trends in the epidemiology of shingles in Alberta.
        Epidemiol Infect. 2007 Aug; 135 (Epub 2007 Feb 12.): 908-913
        • Brisson M
        • Edmunds WJ
        • Gay NJ
        • Law B
        • De Serres G
        Modeling the impact of immunization on the epidemiology of varicella zoster virus.
        Epidemiol Infect. 2000; 125: 651-669
        • Brisson M
        • Gay NJ
        • Edmunds WJ
        • Andrews NJ
        Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox.
        Vaccine. 2002; 20: 2500-2507
        • Brisson M
        • Edmunds WJ
        The cost-effectiveness of varicella vaccination in Canada.
        Vaccine. 2002; 20: 1113-1125
        • Garnett GP
        • Grenfell BT
        The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster.
        Epidemiol Infect. 1992; 108: 513-528
        • Garnett GP
        • Ferguson NM
        Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella.
        Rev Med Virol. 1996; 6: 151-161
        • Jumaan AO
        • Yu O
        • Jackson LA
        • Bohlke K
        • Galil K
        • Seward JF
        Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002.
        J Infect Dis. 2005 Jun 15; 191 (Epub 2005 May 12.): 2002-2007
        • Wagenpfeil S
        • Neiss A
        • Wutzler P
        Effects of varicella vaccination on herpes zoster incidence.
        Clin Microbiol Infect. 2004; 10: 954-960
        • Schuette MC
        • Hethcote HW
        Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles.
        Bull Math Biol. 1999; 61: 1031-1064
        • De Moragas JM
        • Kierland RR
        The outcome of patients with herpes zoster.
        AMA Arch Derm. 1957; 75: 193-196
        • MacIntyre CR
        • Chu CP
        • Burgess MA
        Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia.
        Epidemiol Infect. 2003; 131: 675-682
        • Roger VL
        • Weston SA
        • Redfield MM
        • et al.
        Trends in heart failure incidence and survival in a community-based population.
        JAMA. 2004; 292: 344-350
      1. Pellissier JM, Brisson M, Levin M. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine, In press.

      Linked Article

      • CORRECTION
        Mayo Clinic ProceedingsVol. 83Issue 2
        • Preview
          Incorrect wording: In the article by Yawn et al entitled “A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction,” published in the November 2007 issue of Mayo Clinic Proceedings (Mayo Clin Proc. 2007;82(11): 1341-1349), the 2nd sentence under the heading “Incidence of HZ” on page 1344, left-hand column, contained incorrect wording. The sentence should read as follows: The age-adjusted, sex-specific rates extrapolated to the US population are higher in women than in men (3.9 vs.
        • Full-Text
        • PDF